(5-chlorocarbonyl-pyridin-2-yl)-methyl-carbamic acid tert-butyl ester | 1253281-20-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (5-chlorocarbonyl-pyridin-2-yl)-methyl-carbamic acid tert-butyl ester
• 英文别名: (5-Chlorocarbonyl-pyridin-2-yl)-methyl-carbamic acid tert-butyl ester；tert-butyl N-(5-carbonochloridoylpyridin-2-yl)-N-methylcarbamate
• CAS: 1253281-20-7
• 化学式: C₁₂H₁₅ClN₂O₃
• 分子量: 270.716
• InChiKey: NEVXWWOPWVHVCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  59.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (5-chlorocarbonyl-pyridin-2-yl)-methyl-carbamic acid tert-butyl ester 、 2,6-二氟-3-胺基吡啶 在 吡啶 作用下， 反应 0.5h， 生成
  参考文献：
  名称：

  Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328

  摘要：

  5-Fluoro-2-aryloxazolo[5,4-b]pyridines were synthesized and investigated as potential F-18 containing beta-amyloid PET ligands. In competition binding assays using human AD brain homogenates, compounds 14b, 16b, and 17b were identified as having favorable potency versus human beta-amyloid plaque and were radiolabeled for further evaluation in in vitro binding and in vivo PET imaging experiments. These studies led to the identification of 17b (MK-3328) as a candidate PET ligand for the clinical assessment of beta-amyloid plaque load.

  DOI：

  10.1021/ml200018n
• 作为产物：
  描述：

  6-((叔丁氧基羰基)(甲基)氨基)烟酸 在 1-氯-N,N,2-三甲基丙烯胺 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 (5-chlorocarbonyl-pyridin-2-yl)-methyl-carbamic acid tert-butyl ester
  参考文献：
  名称：

  [EN] THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER
  [FR] THIATRIAZACYCLOPENTAZULÈNES COMME INHIBITEURS DES PI3-KINASES POUR LE TRAITEMENT D'UN CANCER

  摘要：

  本发明涵盖了一般式（1）中的化合物，其中R1至R3和X的定义如权利要求书中所述，适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物。

  公开号：

  WO2010122071A1

文献信息

• [EN] THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] THIATRIAZACYCLOPENTAZULÈNES COMME INHIBITEURS DES PI3-KINASES POUR LE TRAITEMENT D'UN CANCER
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010122071A1

  公开（公告）日：2010-10-28

  The present invention encompasses compounds of general formula (1) wherein 5 R1 to R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式（1）中的化合物，其中R1至R3和X的定义如权利要求书中所述，适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物。
• [EN] THIA-TRIAZA-AS-INDACENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] THIA-TRIAZA-AS-INDACÈNES EN TANT QU'INHIBITEURS DES PI3 KINASES POUR LE TRAITEMENT DU CANCER
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010122091A1

  公开（公告）日：2010-10-28

  The present invention encompasses compounds of general formula (1) wherein R1 to R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式（1）中R1至R3和X如权利要求1所定义的化合物，适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物。
• Thia-triaza-cyclopentazulenes
  申请人：Boehringer Ingelheim International GmbH

  公开号：US08288379B2

  公开（公告）日：2012-10-16

  The present invention encompasses compounds of general formula (1) wherein R1 to R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物，其中R1至R3和X的定义如权利要求书中所述，适用于治疗由过度或异常细胞增殖所表征的疾病，并且其用于制备具有上述特性的药物。
• THIA-TRIAZA-INDACENES
  申请人：Van Der Veen Lars

  公开号：US20120108618A1

  公开（公告）日：2012-05-03

  The present invention encompasses compounds of general formula (1) wherein R 1 to R 3 and X are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式（1）中R1至R3和X如权利要求1所定义的化合物，适用于治疗由过度或异常细胞增殖所特征的疾病，并用于制备具有上述性质的药物。
• Thia-triaza-indacenes
  申请人：Van Der Veen Lars

  公开号：US09243000B2

  公开（公告）日：2016-01-26

  The present invention encompasses compounds of general formula (1) wherein R1 to R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖通式（1）中R1到R3和X如权利要求1所定义的化合物，适用于治疗由过度或异常细胞增殖特征的疾病，并且用于制备具有上述特性的药物。